Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...-- TessArae® LLC, a global leader in resequen...launch of new integrated product solutions for gen...hereditary diseases. The combination of TessArae,...novel nucleotide sequence basecalling algorithms a...geted mutations in multiple genes of a syndrome or...
(Date:11/9/2009)...tCall/ -- Monsanto Company (NYSE: MON ) and Pfize... entered into an agreement for Monsanto to acquire...ated in Chesterfield, Mo. Under the terms of the ... Pfizer for $435 million to be paid over time, and...rfield Village through a lease agreement, primaril...
(Date:11/9/2009)...all/ -- Boston Scientific Corporation (NYSE: BSX ...ardiac resynchronization therapy defibrillator (CR...fibrillator (ICD) in Japan. These devices were ap...nd Welfare (MHLW) in August and received reimburse...e the result of a multi-year research and developm...
Breaking Medicine Technology:TessArae Delivers Lower Cost Option to Genetic Testing Market 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 2Monsanto to Purchase Chesterfield Village Research Center From Pfizer 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4K State Veterinarian Says Owners Should Count How Many Calories Their Obese Pets Take In And Consider Several Factors When Feeding Pets For Good Healt 59110 1K State Veterinarian Says Owners Should Count How Many Calories Their Obese Pets Take In And Consider Several Factors When Feeding Pets For Good Healt 59110 2K State Veterinarian Says Owners Should Count How Many Calories Their Obese Pets Take In And Consider Several Factors When Feeding Pets For Good Healt 59110 3Statewide Drug Card Program Launching 59108 1Roche Scientist Recognized for Excellence in Peptide Chemistry 5312 1Roche Scientist Recognized for Excellence in Peptide Chemistry 5312 2Roche Scientist Recognized for Excellence in Peptide Chemistry 5312 3Roche Scientist Recognized for Excellence in Peptide Chemistry 5312 4
...erapeutic Strategy for ...BioSciences, Inc. (Nasdaq: SGMO ) announced today...immune system cells (CD4 T-cells) can be made,resi...er DNA-binding,protein nucleases (ZFN(TM)). The da... the permanent modification of the CCR5 gene encod...
...U clinical trials in the, United States and abund... CHARLOTTE, N.C., June 27 USHIFU, LLC, the exclu...te(R) 500 for prostate cancer,treatment in North a...,edition of ABC News NIGHTLINE featured a segment ...eating prostate cancer outside of the United State...
Other Medicine Technology:Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 2Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 3Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 4Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 5Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells 6ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 2ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer 3
(Date:11/9/2009)..., SBA Provision, Antitrust Language, Federal T...n Senate ,, WASHINGTON, Nov. 9 /PRNewswire-USN...able Health Care for America Act (H.R. 3962) allow...ed by health insurance exchanges is positive, but ... according to the National Association of Professi...
(Date:11/9/2009)...tudy in mice reports success with drugs that inhib...Day News) -- Two drugs used to treat breast cancer...ce, according to a new study. , The drugs also ...ina, and prevented the onset of cancer in mice wit...g fulvestrant and the breast cancer/osteoporosis d...
(Date:11/9/2009)... Networking is everybody,s...t means Money. StaffingClub.com enables Recruiters...contacts to connect, share, communicate and close ...ekers to post their profiles and network with recr...r 9, 2009 -- Current Job Market forces everyone to...
(Date:11/9/2009)...abbits implanted with new cells regained sexual fu...9 (HealthDay News) -- Researchers were able to res...es by growing new penile tissue in the lab and imp...an application is a ways off, researchers say the ...ectile dysfunction in men. , "We were able to s...
(Date:11/9/2009)... Tomorrow may be too late ...s condition, according to TOPS Club, Inc. (Take Of...ort organization. , (Vocu...en it comes to preventing or improving a diabetes ...Pounds Sensibly), the nonprofit weight-loss suppor...
Breaking Medicine News(10 mins):Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 2Health News:PIA Says Inclusion of Agents in House Healthcare Bill is Positive, But Concerns Remain 3Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3
...at wrestler Benoits' 7-year-old son, Daniel, was s... level of the anti-anxiety drug Xanax was found i...ad a steroid and other drugs in his system when he...the Georgia Bureau of Investigation, released the ...
...t in the July issue of Archives of Surgery,Individ...e intensive care unit , use more ventilator suppor...on for trauma than non-diabetics. Approximat...op complications more frequently and do worse afte...
...(AHS) is a rare neurological disorder that causes ...at is happening or having control over the action ...r objects and manipulate them without wanting to d...n both voluntary and involuntary movement and foun...
...t in the July issue of Archives of Surgery,the rat...by the bacteria Clostridium difficile more than d...tates between 1993 and 2003, and the illness was m...y adults and about 20 percent of patients receivin...
... by a researcher from Saint Louis University Schoo...and depression - genetics . Qiang John Fu,...hat the that a persons genes, that are also associ...nt. Dr. Fu and his team analyzed 3,360 pai...
...cutaneous T-cell lymphoma became substantially mor...2 , according to a report in the July issue of Arc...y by race, sex and geographic area. Cutaneous...pes of lymphoma, according to background informati...
Other Medicine News:Health News:Wrestler Chris Benoits Son was Sedated - Says Investigators 2Health News:Diabetes may Lead to More Complications 2Health News:Alien Hand Syndrome Causes Random Hand Movement 2Health News:Colitis More Common in Hospitalized Patients 2Health News:Colitis More Common in Hospitalized Patients 3Health News:Colitis More Common in Hospitalized Patients 4Health News:Study Finds Genetic Link Between Smoking Addiction and Major Depression 2Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2
...mechanism for speed, stability and durability. Bac...og display modes, multiple units of measure, piece...t, and GLP/GMP/ISO output including date and time ...internal calibration mass for convenient Touch-key...
...mechanism for speed, stability and durability. Bac...og display modes, multiple units of measure, piece...t, and GLP/GMP/ISO output including date and time ...th external weights only (selectable range). Shima...
Thermometer
Digital Thermometer & High-Low Temp Alarm
Medicine Products: